Skip to content

Author

B. Musielak

We have 1 of 72 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy.

Rosavin is identified as a privileged novel and unexpected scaffold for designing potent PD-1/PD-L1 modulators, offering promising candidates for cancer immunotherapy and exhibiting the unusual small-molecule property of inhibiting PD-L1 without inducing its dimerization.

Wei Zou, Tianle Li, Jacek Plewka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.